Heterogeneous activation of the TGFβ pathway in glioblastomas identified by gene expression-based classification using TGFβ-responsive genes

por Xu, Xie L, Kapoun, Ann M
Publicado 2009

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study

por Mease, Philip J., Gladman, Dafna D., Poddubnyy, Denis, Chakravarty, Soumya D., Shawi, May, Kollmeier, Alexa P., Xu, Xie L., Xu, Stephen, Deodhar, Atul, Baraliakos, Xenofon
Publicado 2023

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial

por Helliwell, Philip S., Deodhar, Atul, Gottlieb, Alice B., Boehncke, Wolf-Henning, Xu, Xie L., Xu, Stephen, Wang, Yuhua, Hsia, Elizabeth C., Gladman, Dafna D., Ritchlin, Christopher T.
Publicado 2020

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis...

por Ritchlin, Christopher T., Deodhar, Atul, Boehncke, Wolf‐Henning, Soriano, Enrique R., Kollmeier, Alexa P., Xu, Xie L., Zazzetti, Federico, Shawi, May, Jiang, Yusang, Sheng, Shihong, Helliwell, Philip S.
Publicado 2023

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

por Siebert, Stefan, Sweet, Kristen M., Ritchlin, Christopher T., Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Seridi, Loqmane, Song, Qingxuan, Gao, Sheng, Chen, Warner, Miron, Michelle
Publicado 2023

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, plac...

por Gottlieb, Alice B, McInnes, Iain B, Rahman, Proton, Kollmeier, Alexa P, Xu, Xie L, Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D, Lavie, Frederic, Mease, Philip J
Publicado 2023

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, plac...

por Mease, Philip J, Gladman, Dafna D, Deodhar, Atul, McGonagle, Dennis G, Nash, Peter, Boehncke, Wolf-Henning, Gottlieb, Alice, Xu, Xie L, Xu, Stephen, Hsia, Elizabeth C, Karyekar, Chetan S, Helliwell, Philip S
Publicado 2020

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phas...

por Orbai, Ana-Maria, Coates, Laura C., Deodhar, Atul, Helliwell, Philip S., Ritchlin, Christopher T., Leibowitz, Evan, Kollmeier, Alexa P., Hsia, Elizabeth C., Xu, Xie L., Sheng, Shihong, Jiang, Yusang, Liu, Yan, Han, Chenglong
Publicado 2022

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studi...

por McGonagle, Dennis, McInnes, Iain B., Deodhar, Atul, Schett, Georg, Shawi, May, Chakravarty, Soumya D., Kollmeier, Alexa P., Xu, Xie L., Sheng, Shihong, Xu, Stephen, Ritchlin, Christopher T., Rahman, Proton, Mease, Phillip J.
Publicado 2023

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Bl...

por McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D., van der Heijde, Désirée, Mease, Philip J.
Publicado 2022

Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)

por Schett, Georg, Loza, Matthew J., Palanichamy, Arumugam, FitzGerald, Oliver, Ritchlin, Christopher, Bay-Jensen, Anne-Christine, Nielsen, Signe Holm, Gao, Sheng, Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Baribaud, Frédéric, Sweet, Kristen
Publicado 2022

Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)

por Schett, Georg, Loza, Matthew J., Palanichamy, Arumugam, FitzGerald, Oliver, Ritchlin, Christopher, Bay-Jensen, Anne-Christine, Nielsen, Signe Holm, Gao, Sheng, Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Baribaud, Frédéric, Sweet, Kristen
Publicado 2022

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

por Coates, Laura C, Ritchlin, Christopher T, Gossec, Laure, Helliwell, Philip S, Rahman, Proton, Kollmeier, Alexa P, Xu, Xie L, Shawi, May, Karyekar, Chetan S, Contré, Christine, Noël, Wim, Sheng, Shihong, Wang, Yanli, Xu, Stephen, Mease, Philip J
Publicado 2022

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies

por McGonagle, Dennis, McInnes, Iain B, Deodhar, Atul, Schett, Georg, Shawi, May, Kafka, Shelly, Karyekar, Chetan S, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Ritchlin, Christopher T, Rahman, Proton, Mease, Philip J
Publicado 2021

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 5...

por Ritchlin, Christopher T, Mease, Philip J, Boehncke, Wolf-Henning, Tesser, John, Schiopu, Elena, Chakravarty, Soumya D, Kollmeier, Alexa P, Xu, Xie L, Shawi, May, Jiang, Yusang, Sheng, Shihong, Wang, Yanli, Xu, Stephen, Merola, Joseph F, McInnes, Iain B, Deodhar, Atul
Publicado 2022

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis

por McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Chakravarty, Soumya D., Xu, Xie L., Subramanian, Ramanand A., Agarwal, Prasheen, Sheng, Shihong, Jiang, Yusang, Zhou, Bei, Zhuang, Yanli, van der Heijde, Désirée, Mease, Philip J.
Publicado 2021

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study...

por Ritchlin, Christopher T, Helliwell, Philip S, Boehncke, Wolf-Henning, Soriano, Enrique R, Hsia, Elizabeth C, Kollmeier, Alexa P, Chakravarty, Soumya D, Zazzetti, Federico, Subramanian, Ramanand A, Xu, Xie L, Zuraw, Qing C, Sheng, Shihong, Jiang, Yusang, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Shawi, May, Karyekar, Chetan S, Deodhar, Atul
Publicado 2021